We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+6.08%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$42.8B
AUM Growth
+$3.35B
(+8.5%)
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
14.82%
Holding
2,894
New
39
Increased
2,631
Reduced
168
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$21.8M |
| 2 |
Chevron
CVX
|
+$20.5M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$19.7M |
| 4 |
Incyte
INCY
|
+$17.8M |
| 5 |
ExxonMobil
XOM
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SE
Spectra Energy Corp Wi
SE
|
+$49.6M |
| 2 |
STJ
St Jude Medical
STJ
|
+$41.1M |
| 3 |
LLTC
Linear Technology Corp
LLTC
|
+$30.3M |
| 4 |
HAR
Harman International Industries
HAR
|
+$13.8M |
| 5 |
ENH
Endurance Specialty Holdings Ltd
ENH
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.2% |
| 2 | Technology | 15.06% |
| 3 | Healthcare | 13.05% |
| 4 | Industrials | 10.88% |
| 5 | Consumer Discretionary | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ATRI
1526
DELISTED
Atrion Corp
ATRI
| $2.07M | ﹤0.01% |
4,427
-50
| -1% | -$23.8K |
|
|
NXTM
1527
DELISTED
NxStage Medical Inc.
NXTM
| $2.07M | ﹤0.01% |
77,269
+2,497
| +3% | +$69K |
|
|
SVU
1528
DELISTED
SUPERVALU Inc.
SVU
| $2.07M | ﹤0.01% |
76,524
+20,733
| +37% | +$567K |
|
|
NFBK
1529
DELISTED
Northfield Bancorp
NFBK
| $2.07M | ﹤0.01% |
114,688
+17,030
| +17% | +$314K |
|
|
MDR
1530
DELISTED
McDermott International
MDR
| $2.06M | ﹤0.01% |
101,791
+2,656
| +3% | +$58.5K |
|
1531
Armstrong World Industries
AWI
$7.38B
| $2.06M | ﹤0.01% |
44,697
+2,371
| +6% | +$100K |
|
1532
National Beverage
FIZZ
$2.96B
| $2.06M | ﹤0.01% |
48,696
+1,746
| +4% | +$52.5K |
|
1533
Qualys
QLYS
$5.1B
| $2.06M | ﹤0.01% |
54,305
+16,277
| +43% | +$572K |
|
1534
Liberty Media Series C
FWONK
$24.6B
| $2.05M | ﹤0.01% |
62,100
+2,271
| +4% | +$70K |
|
|
ORIT
1535
DELISTED
Oritani Financial Corp. New
ORIT
| $2.05M | ﹤0.01% |
120,482
+8,476
| +8% | +$146K |
|
1536
Hanmi Financial
HAFC
$945M
| $2.05M | ﹤0.01% |
66,528
+17,789
| +36% | +$586K |
|
1537
SPX Corp
SPXC
$11B
| $2.04M | ﹤0.01% |
84,043
+21,542
| +34% | +$534K |
|
|
HAPN
1538
Happen Inc
HAPN
$2.21B
| $2.03M | ﹤0.01% |
73,923
+3,178
| +4% | +$90.3K |
|
|
SHLM
1539
DELISTED
Schulman (A.) Inc
SHLM
| $2.03M | ﹤0.01% |
64,419
+16,577
| +35% | +$550K |
|
1540
RE/MAX Holdings
RMAX
$193M
| $2.02M | ﹤0.01% |
34,042
+10,050
| +42% | +$570K |
|
|
BEL
1541
DELISTED
Belmond Ltd.
BEL
| $2.02M | ﹤0.01% |
166,830
+44,466
| +36% | +$585K |
|
1542
Installed Building Products
IBP
$6.01B
| $2.01M | ﹤0.01% |
38,181
+11,069
| +41% | +$498K |
|
1543
Dine Brands
DIN
$456M
| $2.01M | ﹤0.01% |
36,952
+9,412
| +34% | +$594K |
|
1544
Renasant Corp
RNST
$3.98B
| $2M | ﹤0.01% |
50,415
+2,698
| +6% | +$109K |
|
|
ISCA
1545
DELISTED
International Speedway Corp
ISCA
| $2M | ﹤0.01% |
54,125
+57
| +0.1% | +$2.1K |
|
|
VIVO
1546
DELISTED
Meridian Bioscience Inc
VIVO
| $2M | ﹤0.01% |
144,796
+24,916
| +21% | +$348K |
|
1547
Tootsie Roll Industries
TR
$2.93B
| $1.99M | ﹤0.01% |
69,631
-543
| -0.8% | -$15.6K |
|
1548
Columbia Sportswear
COLM
$3.04B
| $1.99M | ﹤0.01% |
33,903
+1,346
| +4% | +$75.6K |
|
1549
Ollie's Bargain Outlet
OLLI
$4.44B
| $1.99M | ﹤0.01% |
59,333
+25,893
| +77% | +$814K |
|
1550
Park National Corp
PRK
$3.76B
| $1.99M | ﹤0.01% |
18,899
+737
| +4% | +$80.7K |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2017 Portfolio in Review
As of Q1 2017, RhumbLine Advisers held 2,894 positions worth $42.8B, up 8.5% from $39.5B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
RhumbLine Advisers deployed $1.35B of net new capital in Q1 2017, opening 39 new positions and adding to 2,631 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Biogen, an estimated $8.21M trimmed.
- RhumbLine Advisers's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
- RhumbLine Advisers added most to Abbott in Q1 2017, an estimated $21.8M increase.
- RhumbLine Advisers's biggest Q1 2017 reduction was Biogen, cutting an estimated $8.21M.
- RhumbLine Advisers fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $49.6M.
- RhumbLine Advisers's ten largest holdings make up 15% of its $42.8B portfolio in Q1 2017.
- RhumbLine Advisers opened 39 new positions and closed 44 in Q1 2017.
- RhumbLine Advisers's portfolio value rose 8.5% quarter-over-quarter to $42.8B.
Based on RhumbLine Advisers's 13F filing for Q1 2017, filed 2 May 2017.